278 related articles for article (PubMed ID: 17695453)
21. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
[TBL] [Abstract][Full Text] [Related]
22. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer.
Hara I; Miyake H; Hara S; Yamanaka N; Ono Y; Eto H; Takechi Y; Arakawa S; Kamidono S
BJU Int; 2001 Jul; 88(1):53-7. PubMed ID: 11446846
[TBL] [Abstract][Full Text] [Related]
23. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
Sankin A; Tareen B; Lepor H
Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
[TBL] [Abstract][Full Text] [Related]
24. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
25. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
27. Evolution of the clinical presentation and outcomes after radical prostatectomy for patients with clinically localized prostate cancer--changing trends over a ten year period.
Stimac G; Dimanovski J; Trnski D; Katusić J; Ruzić B; Spajić B; Reljić A; Padovan M; Kraus O
Coll Antropol; 2007 Dec; 31(4):1055-60. PubMed ID: 18217458
[TBL] [Abstract][Full Text] [Related]
28. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
31. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
32. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
Imamoto T; Suzuki H; Fukasawa S; Shimbo M; Inahara M; Komiya A; Ueda T; Shiraishi T; Ichikawa T
Eur Urol; 2005 Mar; 47(3):308-12. PubMed ID: 15716191
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
Furuya Y; Ohta S; Sato N; Kotake T; Sugano I; Nagao K; Masai M
Anticancer Res; 2001; 21(2B):1317-20. PubMed ID: 11396206
[TBL] [Abstract][Full Text] [Related]
35. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
37. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
[TBL] [Abstract][Full Text] [Related]
38. Derivatives of prostate-specific antigen as predictors of incidental prostate cancer.
Froehner M; Buck LM; Koch R; Hakenberg OW; Wirth MP
BJU Int; 2009 Jul; 104(1):25-8. PubMed ID: 19191782
[TBL] [Abstract][Full Text] [Related]
39. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.
Radwan MH; Yan Y; Luly JR; Figenshau RS; Brandes SB; Bhayani SB; Bullock AD; Liefu Y; Andriole GL; Kibel AS
Urology; 2007 Jun; 69(6):1121-7. PubMed ID: 17572199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
